Elliot J Androphy

US Patent:

7183051, Feb 27, 2007

Filed:

Jun 27, 2002

Appl. No.:

10/185369

Inventors:

Elliot J. Androphy - Natick MA, US
Nishita Doshi - Cambridge MA, US
Alexandra Belayew - Esneux, BE

Assignee:

New England Medical Center - Boston MA
University of Mons-Hainaut - Mons

International Classification:

C12Q 1/68
G01N 33/50

US Classification:

435 6, 435 4, 436 63, 436 64

Abstract:

The invention is based on the elucidation of a mechanism by which HPV promotes oncogenesis and provides a methods of diagnosing malignant tumors and methods of preventing the development of malignancies or inhibiting tumor growth. A method for diagnosing a neoplasm in a mammal is carried out by measuring the level of helicase-like transcription factor (HLTF) in tissue of the mammal. An increase in the level of HLTF in the tissue compared to the level in a normal control tissue indicates the presence of a neoplasm in the tissue.

US Patent:

7838657, Nov 23, 2010

Filed:

Dec 5, 2005

Appl. No.:

11/295725

Inventors:

Ravindra N. Singh - Shrewsbury MA, US
Natalia N. Singh - Shrewsbury MA, US
Nirmal K. Singh - Temple TX, US
Elliot J. Androphy - Natick MA, US

Assignee:

University of Massachusetts - Boston MA

International Classification:

C07H 21/04
C07H 21/02
A61K 48/00

US Classification:

536 245, 536 231, 536 2431, 536 2433, 514 44

Abstract:

The present invention is directed to methods and compositions capable of blocking the inhibitory effect of a newly-identified intronic inhibitory sequence element, named ISS-N1 (for “intronic splicing silencer”), located in the SMN2 gene. The compositions and methods of the instant invention include oligonucleotide reagents (e. g. , oligoribonucleotides) that effectively target the SMN2 ISS-N1 site in the SMN2 pre-mRNA, thereby modulating the splicing of SMN2 pre-mRNA to include exon 7 in the processed transcript. The ISS-N1 blocking agents of the invention cause elevated expression of SMN protein, thus compensating for the loss of SMN protein expression commonly observed in subjects with spinal muscular atrophy (SMA).

US Patent:

7914769, Mar 29, 2011

Filed:

Apr 7, 2005

Appl. No.:

11/100709

Inventors:

Elliot J. Androphy - Natick MA, US
James D. Baleja - Boston MA, US

Assignee:

University of Massachusetts - Boston MA
Tufts University - Medford MA

International Classification:

A61K 49/00
A61K 31/165

US Classification:

424 92, 514622

Abstract:

Methods and compositions for treating human papillomavirus infections are described.

US Patent:

8110560, Feb 7, 2012

Filed:

Aug 21, 2009

Appl. No.:

12/545536

Inventors:

Ravindra N. Singh - Shrewsbury MA, US
Natalia N. Singh - Shrewsbury MA, US
Nirmal K. Singh - Temple TX, US
Elliot J. Androphy - Natick MA, US

Assignee:

University of Massachusetts - Boston MA

International Classification:

A61K 48/00
C07H 21/04
C07H 21/02

US Classification:

514 44, 536 231, 536 2431, 536 2433, 536 245

Abstract:

The present invention is directed to methods and compositions capable of blocking the inhibitory effect of a newly-identified intronic inhibitory sequence element, named ISS-N1 (for “intronic splicing silencer”), located in the SMN2 gene. The compositions and methods of the instant invention include oligonucleotide reagents (e. g. , oligoribonucleotides) that effectively target the SMN2 ISS-N1 site in the SMN2 pre-mRNA, thereby modulating the splicing of SMN2 pre-mRNA to include exon 7 in the processed transcript. The ISS-N1 blocking agents of the invention cause elevated expression of SMN protein, thus compensating for the loss of SMN protein expression commonly observed in subjects with spinal muscular atrophy (SMA).

US Patent:

8586559, Nov 19, 2013

Filed:

Dec 19, 2011

Appl. No.:

13/329926

Inventors:

Ravindra N. Singh - Shrewsbury MA, US
Natalia N. Singh - Shrewsbury MA, US
Nirmal K. Singh - Temple TX, US
Elliot J. Androphy - Natick MA, US

Assignee:

University of Massachusetts - Boston MA

International Classification:

A61K 48/00
C07H 21/04

US Classification:

514 44, 536 234, 536 2431, 536 3433

Abstract:

The present invention is directed to methods and compositions capable of blocking the inhibitory effect of a newly-identified intronic inhibitory sequence element, named ISS-N1 (for “intronic splicing silencer”), located in the SMN2 gene. The compositions and methods of the instant invention include oligonucleotide reagents (e. g. , oligoribonucleotides) that effectively target the SMN2 ISS-N1 site in the SMN2 pre-mRNA, thereby modulating the splicing of SMN2 pre-mRNA to include exon 7 in the processed transcript. The ISS-N1 blocking agents of the invention cause elevated expression of SMN protein, thus compensating for the loss of SMN protein expression commonly observed in subjects with spinal muscular atrophy (SMA).

US Patent:

20110172311, Jul 14, 2011

Filed:

Mar 28, 2011

Appl. No.:

13/073401

Inventors:

Elliot J. Androphy - Natick MA, US
James D. Baleja - Boston MA, US

International Classification:

A61K 31/167
A61P 31/20
G01N 33/566

US Classification:

514622, 436501

Abstract:

Methods and compositions for treating human papillomavirus infections are described.

US Patent:

20130096160, Apr 18, 2013

Filed:

Apr 14, 2011

Appl. No.:

13/641383

Inventors:

Juan Jose Marugan - Gaithersburg MD, US
Jingbo Xiao - Rockville MD, US
Steven A. Titus - Elkridge MD, US
Noel Southall - Chevy Chase MD, US
Wei Zheng - Potomac MD, US
Elliot J. Androphy - Natick MA, US
Jonathan Cherry - Worcester MA, US

Assignee:

Secretary, Department of Health and Human Services - Bethesda MD

International Classification:

C07D 417/04

US Classification:

514326, 546209

Abstract:

Aryl substituted thiazol-2-yl-piperidines and related compounds useful as modulators of survival motor neuron (SMN) protein production are provided herein. Without being bound to any particular theory it is believed the aryl substituted thiazol-2-yl-piperidines and related compounds provided herein act to increase production of the SMN2 form of survival motor neuron protein. These compounds are useful for treating spinal muscular atrophy. Pharmaceutical compositions containing a carrier and one or more of the aryl substituted thiazol-2-yl-piperidine or related compounds described herein are also provided. Methods of treating spinal muscular atrophy are also provided by this disclosure.

US Patent:

20140066492, Mar 6, 2014

Filed:

Oct 15, 2013

Appl. No.:

14/054055

Inventors:

Natalia N. SINGH - Shrewsbury MA, US
Nirmal K. SINGH - Temple TX, US
Elliot J. ANDROPHY - Natick MA, US

Assignee:

UNIVERSITY OF MASSACHUSETTS - Boston MA

International Classification:

C12N 15/113

US Classification:

514 44 A, 536 245, 435375

Abstract:

The present invention is directed to methods and compositions capable of blocking the inhibitory effect of a newly-identified intronic inhibitory sequence element, named ISS-N1 (for “intronic splicing silencer”), located in the SMN2 gene. The compositions and methods of the instant invention include oligonucleotide reagents (e.g., oligoribonucleotides) that effectively target the SMN2 ISS-N1 site in the SMN2 pre-mRNA, thereby modulating the splicing of SMN2 pre-mRNA to include exon 7 in the processed transcript. The ISS-N1 blocking agents of the invention cause elevated expression of SMN protein, thus compensating for the loss of SMN protein expression commonly observed in subjects with spinal muscular atrophy (SMA).